Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference

CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- ^® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a virtual fireside chat at the 2022 BofA Securities Biotech SMID Cap Conference, on Thursday, December 8, 2022 at 9:10 a.m. ET

A live audio webcast will be available through the Investor Relations section of the Fulcrum website at . An archived replay will be available on the Company’s website for 30 days.

About Fulcrum Therapeutics 

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. Fulcrum’s proprietary product engine, FulcrumSeek™, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit  and follow us on .

Contacts:

Investors

Stephanie Ascher

Stern Investor Relations, Inc.



212-362-1200

Media

Dee Smith

Executive Director, Corporate Communications

Fulcrum Therapeutics, Inc.



202-746-1324